KT-501

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameKT-501
Drug Alias NameKT501KT-501
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD19Anti-BCMAAnti-CD3
TargetsB-lymphocyte antigen CD19B-cell maturation proteinT cell surface glycoprotein CD3
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesKali Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesKali Therapeutics IncSanofi
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A